pHLIP-STINGa

pHLIP-STINGa is a preclinical, tumor-acidity-targeted peptide-drug conjugate designed for cancer immunotherapy. It links a pH-Low Insertion Peptide pHLIP Var3 to the small-molecule STING agonist diABZI through a self-immolating, disulfide-cleavable linker. In acidic solid-tumor microenvironments, pHLIP inserts into cell membranes and delivers diABZI intracellularly to tumor-associated stromal and immune cells, including cancer-associated fibroblasts, tumor-associated macrophages, myeloid-derived suppressor cells, and dendritic cells. Intracellular STING activation induces local cytokine signaling and antitumor immunity. Published murine studies reported regression or eradication of CT26 colorectal tumors after systemic dosing, durable protection on tumor rechallenge, and inhibition of B16F10 melanoma growth. The name encompasses L-amino-acid and D-amino-acid pHLIP conjugate variants, so it does not identify one fully unique molecular species. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9622777/))

Other names

pHLIP-STINGa